Indications
Mupirocin ointment (Bactoderm ointment), 2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus, beta hemolytic Streptococcus, and Streptococcus pyogenes.
Dosage and administration
A small amount of Mupirocin ointment (Bactoderm ointment), 2% should be applied to the affected area up to three times daily up to 10 days. The area treated may be covered with gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be reevaluated.
Precautions: If hypersensitivity reaction or chemical irritation should occur with the use of Mupirocin ointment, treatment should be discontinued and appropriate alternative therapy for the infection instituted. As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. Mupirocin ointment is not formulated for use on mucosal surfaces. Intranasal use has been associated with isolated reports of stinging pain and drying. Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol-based ointments, Mupirocin ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.
Use in pregnancy and lactation: Reproduction studies have been performed in rats and rabbits at systemic doses, i.e., orally, subcutaneously, and intramuscularly, up to 100 times the human topical dose and have revealed no evidence of impaired fertility or harm to the fetus due to Mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, Mupirocin should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Mupirocin ointment is given to nursing mother.
Use in pediatric patient: The safety and effectiveness of Mupirocin ointment have been established in the age range of 2 months to 16 years. Use of Mupirocin ointment in these age groups is supported by evidence from adequate and well-controlled studies.
Side-effects: Burning, stinging, or pain in 1.5% of patients; itching in 1% of patients; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate in less than 1% of patients. Systemic reactions to Mupirocin ointment have occured rarely.
Reviews
There are no reviews yet.